Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14295795 | 0.80 | MAPT (0.35) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6684736 | 0.80 | ADORA2A (0.42) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9761190 | 0.78 | TSHR (0.37) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9353447 | 0.78 | TDP1 (0.39) | DYRK1AMAPTHTTNPC1RAB9A | |
| SCHEMBL2542592 | 0.78 | MEN1 (0.39) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2913507 | 0.74 | TDP1 (0.39) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9762284 | 0.71 | ALDH1A1 (0.35) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31686443 | 0.68 | ADORA2A (0.44) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1774571 | 0.68 | HTT (0.51) | DYRK1AMAPTHTTNPC1RAB9A | |
| SCHEMBL5281912 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4525875-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023224894-A9 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024184550-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-09-12 | — | — | WO | disclosed |
| WO-2023224894-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-109890846-A | anti-CD 27 antibodies | 默沙东公司 | 2019-06-14 | — | — | CN | disclosed |
| CN-105307656-B | Quinoline inhibitors of macrophage stimulating 1 receptor MST1R | 利德发现中心有限责任公司 | 2019-02-19 | — | — | CN | disclosed |
| CN-108676800-A | The inhibition led using the mediated rnai of hepatitis type B virus (HBV) gene expression of short interfering nucleic acid (siNA) | 瑟纳治疗公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-108289922-A | Therapeutic methods and compositions for treating non-small cell lung cancer | 友杏生技医药股份有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-103946223-B | 3-cyanaryl-1h-pyrazolo[2.3-b]pyridine derivatives | 默克专利股份公司 | 2017-01-18 | — | — | CN | disclosed |
| CN-103153951-A | Pyrrolidones as MetAP-2 inhibitors | MERCK PATENT GMBH | 2013-06-12 | — | — | CN | disclosed |
| CN-101535268-B | Tyrosine kinase inhibitors | MERCK SHARP & DOHME | 2012-11-14 | — | — | CN | disclosed |
| CN-101932572-A | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | MERCK & CO INC | 2010-12-29 | — | — | CN | disclosed |
| CN-101855221-A | Pyridazinone derivatives as PARP inhibitors | ANGELETTI P IST RICHERCHE BIO | 2010-10-06 | — | — | CN | disclosed |
| CN-101808518-A | Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors | MERCK & CO INC | 2010-08-18 | — | — | CN | disclosed |
| CN-101600706-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2009-12-09 | — | — | CN | disclosed |
| CN-101578279-A | Amide substituted indazoles as poly (ADP ribose) polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-11-11 | — | — | CN | disclosed |
| CN-101203495-A | Benzocycloheptapyridine compounds as inhibitors of receptor tyrosine kinase MET | MERCK & CO INC (US) | 2008-06-18 | — | — | CN | disclosed |
| US-4969946-A | HALOGENATED PYRAZOLES | THE DOW CHEMICAL COMPANY (US) | 1990-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313575-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | DYRK1A 400/4885MAPT 528/4885HTT 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.